The FDA update was based on results of the FOURIER trial, which showed the drug reduced the risk of heart attacks, strokes, and revascularizations in high-risk patients. FDA on Friday approved ...
Amgen Inc. AMGN received favorable news with the FDA approving its supplemental new drug application for Kyprolis in combination with dexamethasone or with Celgene Corporation’s CELG Revlimid plus ...
Amgen's cholesterol drug Repatha has a new use in Europe, as the company continues in its battle with Sanofi/Regeneron's rival therapy, Praluent. A PCSK9 inhibitor class drug, Repatha (evolocumab) is ...
US regulators have approved Amgen’s Repatha as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularisations in adults with cardiovascular disease. US regulators have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback